![\"\"](\"http:\/\/kreftgenomikk.no\/files\/2015\/07\/NatureTop.png\")
<\/a><\/h2>\nNorway to bring cancer-gene tests to the clinic<\/h2>\n
A pilot programme will use latest tumour-sequencing techniques to help guide cancer care.<\/strong><\/p>\nIn its three-year pilot phase, the Norwegian Cancer Genomics Consortium will sequence the tumour genomes of 1,000 patients in the hope of influencing their treatments.<\/p>\n
Read more<\/a><\/strong><\/em><\/p>\n![\"\"](\"http:\/\/kreftgenomikk.no\/files\/2015\/07\/LancetTop.png\")
<\/strong><\/em><\/a><\/p>\nI en leder i Lancet brukes NCGC som et eksempel overfor det engelske National Health Service p\u00e5 hvordan man b\u00f8r g\u00e5 frem for \u00e5 innf\u00f8re persontilpasset medisin i helsevesenet:<\/p>\n
Editorial:\u00a0Genomic medicine and the NHS: it is possible<\/h2>\n
\u2026<\/p>\n
\u201cThe advisory group noted that the UK must act quickly to avoid being left behind in this field\u2014a point illustrated by the recent launch of the\u00a0Norwegian Cancer Genomics Consortium<\/a>, a national collaboration for genome-based diagnostics in cancer treatment. Responding to the report, Health Secretary Andrew Lansley announced plans for a new commissioning and funding structure for molecular testing in UK cancer care, to be complete by April, 2013. This is welcome news in the build up to Feb 4\u2019s\u00a0World Cancer Day<\/a>, for which this year\u2019s theme is \u201cTogether it is possible\u201d. This mantra might well be applied to the HGSG\u2019s recommendations. Large-scale adoption of genomic technology could revolutionise the health service\u2014achieving it will require collaboration across many key groups, from policy makers to researchers, industry, and health-care workers.\u201d<\/p>\nRead more<\/strong><\/em><\/a><\/p>\n![\"\"](\"http:\/\/kreftgenomikk.w.uib.no\/files\/2015\/07\/PHGtop.png\")
<\/strong><\/em><\/a><\/p>\nDen engelske\u00a0PHG Foundation<\/a>, en tenketank for\u00a0\u201cpublic health genetics\u201d, knyttet til Universitetet i Cambridge, kommenterte ogs\u00e5 initiativet, og\u00a0skriver:<\/p>\n\u201cThe research evidence (to demonstrate potential improvements in care and outcomes) is a crucial base for moving new technologies such as genome sequencing into clinical practice, but the Norwegian approach is wise to take account of other equally vital considerations such as having nationally agreed protocols and systems to handle and process new testing and data, as well as efforts to underpin health professional and public education, and provide health economic impact data. These are precisely the sorts of measures\u00a0recently recommended<\/a>\u00a0for the clinical implementation of genome sequencing for both cancer and inherited disease services in the UK by the PHG Foundation.\u201d<\/p>\nRead more<\/a><\/strong><\/em><\/p>\n![\"\"](\"http:\/\/kreftgenomikk.w.uib.no\/files\/2015\/07\/natureBiotechTop.png\")
<\/a><\/p>\n\u00a0Reading cancer\u2019s blueprint<\/h2>\n
Ola Myklebost ble ogs\u00e5 intervjuet om NCGC i Nature Biotechnology:<\/em><\/p>\nHowever, the field may receive the greatest boost from a series of national and multinational initiatives now under way in Europe. Among the most notable of these is the Norwegian Cancer Genomics Consortium, a project initiated by research groups at hospitals across the nation, with growing support from pharma and biotech companies. If successful, the consortium could become the world\u2019s first nationwide initiative to sequence tumor and healthy tissue from every cancer patient. \u201cWe\u2019re getting started now on planning to sequence exomes from a couple thousand patient samples, both tumor and blood, across eight different cancer types,\u201d says Ola Myklebost, a group leader at Oslo University and lead principal investigator for the consortium. He notes that Norway\u2019s government-run health system should prove a boon to the project. \u201cVirtually all cancer treatment is through the public health service,\u201d he says, \u201cand we have a national cancer registry that has a very good track record for following the entire population.\u201d<\/p>\n
In its three-year pilot phase, the Norwegian Cancer Genomics Consortium will sequence the tumour genomes of 1,000 patients in the hope of influencing their treatments.<\/p>\n
Read more<\/a><\/strong><\/em><\/p>\n I en leder i Lancet brukes NCGC som et eksempel overfor det engelske National Health Service p\u00e5 hvordan man b\u00f8r g\u00e5 frem for \u00e5 innf\u00f8re persontilpasset medisin i helsevesenet:<\/p>\n \u2026<\/p>\n \u201cThe advisory group noted that the UK must act quickly to avoid being left behind in this field\u2014a point illustrated by the recent launch of the\u00a0Norwegian Cancer Genomics Consortium<\/a>, a national collaboration for genome-based diagnostics in cancer treatment. Responding to the report, Health Secretary Andrew Lansley announced plans for a new commissioning and funding structure for molecular testing in UK cancer care, to be complete by April, 2013. This is welcome news in the build up to Feb 4\u2019s\u00a0World Cancer Day<\/a>, for which this year\u2019s theme is \u201cTogether it is possible\u201d. This mantra might well be applied to the HGSG\u2019s recommendations. Large-scale adoption of genomic technology could revolutionise the health service\u2014achieving it will require collaboration across many key groups, from policy makers to researchers, industry, and health-care workers.\u201d<\/p>\n Read more<\/strong><\/em><\/a><\/p>\n Den engelske\u00a0PHG Foundation<\/a>, en tenketank for\u00a0\u201cpublic health genetics\u201d, knyttet til Universitetet i Cambridge, kommenterte ogs\u00e5 initiativet, og\u00a0skriver:<\/p>\n \u201cThe research evidence (to demonstrate potential improvements in care and outcomes) is a crucial base for moving new technologies such as genome sequencing into clinical practice, but the Norwegian approach is wise to take account of other equally vital considerations such as having nationally agreed protocols and systems to handle and process new testing and data, as well as efforts to underpin health professional and public education, and provide health economic impact data. These are precisely the sorts of measures\u00a0recently recommended<\/a>\u00a0for the clinical implementation of genome sequencing for both cancer and inherited disease services in the UK by the PHG Foundation.\u201d<\/p>\n Read more<\/a><\/strong><\/em><\/p>\n Ola Myklebost ble ogs\u00e5 intervjuet om NCGC i Nature Biotechnology:<\/em><\/p>\n However, the field may receive the greatest boost from a series of national and multinational initiatives now under way in Europe. Among the most notable of these is the Norwegian Cancer Genomics Consortium, a project initiated by research groups at hospitals across the nation, with growing support from pharma and biotech companies. If successful, the consortium could become the world\u2019s first nationwide initiative to sequence tumor and healthy tissue from every cancer patient. \u201cWe\u2019re getting started now on planning to sequence exomes from a couple thousand patient samples, both tumor and blood, across eight different cancer types,\u201d says Ola Myklebost, a group leader at Oslo University and lead principal investigator for the consortium. He notes that Norway\u2019s government-run health system should prove a boon to the project. \u201cVirtually all cancer treatment is through the public health service,\u201d he says, \u201cand we have a national cancer registry that has a very good track record for following the entire population.\u201d<\/p>\n<\/strong><\/em><\/a><\/p>\nEditorial:\u00a0Genomic medicine and the NHS: it is possible<\/h2>\n
<\/strong><\/em><\/a><\/p>\n<\/a><\/p>\n\u00a0Reading cancer\u2019s blueprint<\/h2>\n
![\"\"](\"http:\/\/kreftgenomikk.w.uib.no\/files\/2015\/07\/PMC.gif\")
<\/a><\/p>\n![\"\"](\"http:\/\/kreftgenomikk.no\/files\/2015\/07\/Screen-Shot-2015-07-17-at-12.57.10.png\")
<\/p>\n